Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

Advarra, the market leader in regulatory review solutions and clinical research technology for sites, sponsors, and clinical ...

As the hostilities in the wider Middle East escalate, 7 October 2024 marks one-year since the Hamas-Israel conflict began. Israel's response escalated into conflicts with other organisations, ...

Pythons to highly venomous king browns, the course offered in the Northern Territory at TAFE seeks to prepare students for every kind of slithery encounter. A letter seen by the ABC shows the ...

The prime ministers of Malaysia and Pakistan have agreed to increase bilateral trade and boost economic ties after talks in ...

Focus changed how many fans followed the NFL by providing grades and advanced statistics to help quantify how every player ...

US President Joe Biden says he would not support any Israeli strike on Iran's nuclear sites in response to its ballistic missile attack, urging Israel to act "proportionally".